Modus Therapeutics AB
Swedish biotech developing sevuparin for severe inflammatory diseases.
Översikt
- Okänt
- Anställda
- Okänt
- Omsättning
- 2004
- Grundat
Nyckelbeslutsfattare
John Öhd
Chief Executive Officer
Johan Dighed
Board member
Viktor Drvota
Chairman
Michael Forer
Member of the Nomination Committee
+3 fler kontakter i Funnelfeedr
Beskrivning
Modus Therapeutics is a Swedish biotechnology company focused on developing novel treatments for severe medical conditions with high unmet needs. Their proprietary polysaccharide, sevuparin, is the core asset under development. Sevuparin is designed as a heparinoid that modifies inflammation while m...